Journey Medical Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Journey Medical Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.86M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $56.13M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $79.18M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $73.67M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $63.13M | Mar 31, 2023 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.24M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $55.13M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $59.66M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $71.00M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $63.13M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $44.53M | Mar 28, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($11.43M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($14.67M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($3.85M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($29.63M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($43.99M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $5.28M | Mar 28, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.17M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($13.68M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($2.07M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($27.52M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($34.88M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $7.85M | Mar 28, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $480.0K | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $9.86M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $7.54M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $10.94M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $2.74M | Mar 31, 2023 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.37M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $40.20M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $43.91M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $59.47M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $39.83M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $22.09M | Mar 28, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.44M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($9.13M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $5.24M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($13.53M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($2.18M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $5.13M | Mar 28, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $94.59M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $80.24M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $76.85M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $105.16M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $97.28M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $51.91M | Mar 28, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.74M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $60.17M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $56.50M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $88.18M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $55.24M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $41.61M | Mar 28, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.85M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $20.07M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $20.35M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $16.98M | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | $42.04M | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | $10.29M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $2.75M | Mar 28, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($98.46M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($87.03M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($72.36M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($68.50M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($38.87M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $5.12M | Mar 28, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.09M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $20.31M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $27.44M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $32.00M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $49.08M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $8.25M | Mar 28, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.28M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $24.88M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $14.62M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $27.77M | Mar 29, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | (4) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 28, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | (4) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 28, 2022 |